Regeneron: Eylea Competition Coming but Pipeline Could Maintain Growth

- Eylea represents a significant portion of revenue and will face upcoming competition, which could slow Regeneron sales growth over the coming years

- Eylea recently received approval for a 12 week dose, but with cautious language on the label, leaving the door open for competitors to potentially take share when they enter the market.

- Dupixent is a promising asset that could drive growth after Eylea, but will need to get past reimbursement issues and execute on indication expansions to stay ahead of competition.

Read More